Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SGMO
stocks logo

SGMO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
40.25M
+433.04%
-0.028
-74.85%
20.55M
+219.25%
-0.063
-54.76%
21.50M
+17.45%
-0.063
-20.84%
Estimates Revision
The market is revising Downward the revenue expectations for Sangamo Therapeutics, Inc. (SGMO) for FY2025, with the revenue forecasts being adjusted by -9.49% over the past three months. During the same period, the stock price has changed by -3.13%.
Revenue Estimates for FY2025
Revise Downward
down Image
-9.49%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+20.43%
In Past 3 Month
Stock Price
Go Down
down Image
-3.13%
In Past 3 Month
Wall Street analysts forecast SGMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGMO is 4.33 USD with a low forecast of 1.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast SGMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGMO is 4.33 USD with a low forecast of 1.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 0.530
sliders
Low
1.00
Averages
4.33
High
10.00
Current: 0.530
sliders
Low
1.00
Averages
4.33
High
10.00
Barclays
Overweight -> Equal Weight
downgrade
$5 -> $1
2025-11-07
Reason
Barclays
Price Target
$5 -> $1
2025-11-07
downgrade
Overweight -> Equal Weight
Reason
Barclays downgraded Sangamo to Equal Weight from Overweight with a price target of $1, down from $5. The company's Q3 report highlighted the FDA's reaffirmation of an accelerated approval path using eGFR slope as the endpoint and its cash runway has been extended into Q1 of 2026, the analyst tells investors in a research note. Barclays steps to the sidelines pending further clarity on a Fabry deal.
Barclays
Overweight
downgrade
$9 -> $5
2025-05-14
Reason
Barclays
Price Target
$9 -> $5
2025-05-14
downgrade
Overweight
Reason
Barclays lowered the firm's price target on Sangamo to $5 from $9 and keeps an Overweight rating on the shares. The company's Q1 call provided additional color on cash runway extended into late Q3 by the capital raise, the analyst tells investors in a research note.
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$10
2025-04-07
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$10
2025-04-07
Reiterates
Strong Buy
Reason
RBC Capital
Luca Issi
Hold
Reiterates
$2
2025-03-18
Reason
RBC Capital
Luca Issi
Price Target
$2
2025-03-18
Reiterates
Hold
Reason
Truist Securities
Nicole Germino
Strong Buy
Maintains
$7 → $5
2025-01-23
Reason
Truist Securities
Nicole Germino
Price Target
$7 → $5
2025-01-23
Maintains
Strong Buy
Reason
Truist analyst Nicole Germino lowered the firm's price target on Sangamo to $5 from $7 and keeps a Buy rating on the shares. The firm is updating its model to reflect the return of a BLA-ready Phase 3 asset with competitive data in Hem A and pending more clarity on the longer-term cash position from a potentially near-term announcement of a partner for Phase 3 Fabry disease asset and additional capsid partnerships, the analyst tells investors in a research note. Truist adds that the longer-term cash runway for Sangamo hinges on a partner for Fabry, which may come with a meaningful upfront and royalties payments, removing the cash overhang.
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$10
2025-01-02
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$10
2025-01-02
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Sangamo Therapeutics Inc (SGMO.O) is -2.47, compared to its 5-year average forward P/E of -4.36. For a more detailed relative valuation and DCF analysis to assess Sangamo Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.36
Current PE
-2.47
Overvalued PE
0.18
Undervalued PE
-8.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
1.11
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
27.31
Undervalued EV/EBITDA
-25.09

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.49
Current PS
0.00
Overvalued PS
11.60
Undervalued PS
1.39
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

SGMO News & Events

Events Timeline

(ET)
2025-12-02
08:31:00
Sangamo Receives FDA Fast Track Designation for ST-503 to Treat Small Fiber Neuropathy Pain
select
2025-11-21 (ET)
2025-11-21
08:08:47
Sangamo Reports FDA Approval of Rolling Submission Request for ST-920 BLA
select
2025-11-06 (ET)
2025-11-06
08:12:30
Sangamo projects operating expenses of $135M-$155M for FY25
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-02Globenewswire
PinnedSangamo Receives FDA Fast Track Designation for ST-503 in Chronic Pain Treatment
  • Fast Track Designation: Sangamo Therapeutics announced that its ST-503 has received FDA Fast Track Designation, aimed at expediting the development of treatments for intractable pain due to small fiber neuropathy (SFN), indicating the drug's potential to address significant unmet medical needs.
  • Clinical Trial Preparation: The company is preparing for the Phase 1/2 STAND study, with plans to dose the first patient in the coming months, aimed at assessing the safety and preliminary efficacy of ST-503, thereby advancing its clinical development.
  • Urgent Patient Need: Small fiber neuropathy is a debilitating chronic pain disorder with limited effective treatment options currently available, and the development of ST-503 could provide a new non-opioid treatment alternative for this high unmet need patient population, potentially improving their quality of life.
  • Data Support: Sangamo presented nonclinical data at the International Congress on Neuropathic Pain, demonstrating the durability, potency, and selectivity of ST-503 in nonhuman primates, supporting its application in chronic neuropathic pain treatment.
[object Object]
Preview
9.0
12-02SeekingAlpha
PinnedSangamo Soars After FDA Awards Fast Track Designation to Neuropathic Pain Treatment

  • Sangamo Therapeutics Stock Movement: Sangamo Therapeutics (SGMO) saw a ~16% increase in premarket trading after receiving Fast Track designation from the US FDA for its pain treatment candidate, ST-503.

  • Clinical Trial Progress: The ST-503 candidate is currently in the phase 1/2 STAND trial, with enrollment ongoing and dosing expected to start in the coming months.

  • Target Gene: ST-503 targets the SCN9A gene, which is associated with various inherited neuropathies, as stated by the company.

  • Preclinical Findings: Recent preclinical data indicated that ST-503 effectively repressed SCN9A in dorsal root ganglion levels in nonhuman primates.

[object Object]
Preview
9.0
11-24Newsfilter
Sangamo Receives FDA Acceptance for Gene Therapy BLA Submission
  • FDA Acceptance: Sangamo Therapeutics announced that the FDA has accepted its request for a rolling submission and review of the Biologics License Application (BLA) for isaralgagene civaparvovec, a gene therapy for Fabry disease. This milestone represents a significant step towards accelerated approval, with plans to initiate submission in Q4 2025.
  • Clinical Data Support: At the International Congress of Inborn Errors of Metabolism, Sangamo presented clinical data from the Phase 1/2 STAAR study, showing a positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52 weeks. This data provides crucial support for FDA approval, indicating the therapy's potential as a durable treatment option.
  • Multiple Designations: Isaralgagene civaparvovec has received Orphan Drug, Fast Track, and RMAT designations from the FDA, along with Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency. These designations highlight the therapy's potential value and urgency in the market, potentially expediting its path to commercialization.
  • Broad Market Potential: Fabry disease is a severe genetic disorder affecting multiple vital organs, and Sangamo's therapy could offer significant clinical benefits to patients. With increasing demand for effective treatment options, the successful launch of this therapy could present substantial market opportunities for the company.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Sangamo Therapeutics Inc (SGMO) stock price today?

The current price of SGMO is 0.5301 USD — it has increased 6.21 % in the last trading day.

arrow icon

What is Sangamo Therapeutics Inc (SGMO)'s business?

Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.

arrow icon

What is the price predicton of SGMO Stock?

Wall Street analysts forecast SGMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGMO is 4.33 USD with a low forecast of 1.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Sangamo Therapeutics Inc (SGMO)'s revenue for the last quarter?

Sangamo Therapeutics Inc revenue for the last quarter amounts to 581.00K USD, decreased -98.82 % YoY.

arrow icon

What is Sangamo Therapeutics Inc (SGMO)'s earnings per share (EPS) for the last quarter?

Sangamo Therapeutics Inc. EPS for the last quarter amounts to -0.11 USD, decreased -375.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Sangamo Therapeutics Inc (SGMO)'s fundamentals?

The market is revising Downward the revenue expectations for Sangamo Therapeutics, Inc. (SGMO) for FY2025, with the revenue forecasts being adjusted by -9.49% over the past three months. During the same period, the stock price has changed by -3.13%.
arrow icon

How many employees does Sangamo Therapeutics Inc (SGMO). have?

Sangamo Therapeutics Inc (SGMO) has 183 emplpoyees as of December 05 2025.

arrow icon

What is Sangamo Therapeutics Inc (SGMO) market cap?

Today SGMO has the market capitalization of 178.34M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free